Business Context and Reporting Period
This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on September 19, 2017. The filing addresses corporate governance changes, specifically the departure of a director and the election of a new director, effective immediately on the report date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to a recent rights offering and director compensation:
- Recent Capital Raise: Puissance Cross-Border Opportunities II LLC purchased 20,534,898 shares for an aggregate price of $20.5 million.
- Shareholder Ownership: Following the offering, Puissance holds approximately 34% of issued and outstanding shares.
- Director Compensation: New director Dr. Ted Wang received an option to purchase 37,500 shares at $1.15 per share, an annual retainer of $35,000, and a committee fee of $3,750 per year.
Material Changes
The primary material change is the composition of the Board of Directors:
- Departure: Dan Boren resigned as a Director and Chair of the Nominating and Governance Committee. The resignation was not due to any disagreement with the Company.
- Appointment: Ted Wang, Ph.D., was appointed to fill the vacancy. Dr. Wang is the Chief Investment Officer of Puissance Capital Management LP and a former Partner at Goldman Sachs & Co.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the board changes. No specific financial guidance, outlook, or new risk factors were disclosed in this filing. The appointment of Dr. Wang is linked to the recent rights offering, indicating continued support from a major shareholder.
Investor Verification Checklist
- Verify the impact of the 34% ownership stake held by Puissance on future corporate governance and strategic decisions.
- Confirm the terms of the recent rights offering and the total capital raised beyond the $20.5 million committed by Puissance.
- Review the full resignation letter of Dan Boren (Exhibit 99.1) to ensure no undisclosed conflicts exist.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no operational or financial results.